Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 2/20 | 0.51 |
| ▸ | DRD5 | P21918 | 2/20 | 0.51 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14385483 | 0.86 | HSD17B10 (0.49) | ITGB3ITGA2BCD274ESR1ESR2 | |
| SCHEMBL7128888 | 0.84 | ESR1 (0.51) | CD274ESR1ESR2PRMT5HDAC1 | |
| SCHEMBL915006 | 0.82 | DRD1 (0.59) | ESR1ESR2PRMT5DRD1DRD5 | |
| SCHEMBL29651184 | 0.82 | DRD1 (0.59) | ESR1ESR2PRMT5DRD1DRD5 | |
| SCHEMBL7798191 | 0.82 | ITGB3 (0.54) | ITGB3ITGA2BCD274ESR1ESR2 | |
| SCHEMBL6806983 | 0.81 | L3MBTL1 (0.68) | — | |
| SCHEMBL6369681 | 0.81 | HRH3 (0.61) | ESR1ESR2PRMT5DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL14876546 | 0.80 | L3MBTL1 (0.66) | — | |
| SCHEMBL7798156 | 0.80 | ITGB3 (0.54) | ITGB3ITGA2BCD274ESR1ESR2 | |
| SCHEMBL3428843 | 0.79 | RYR2 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
| US-6159964-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0895475-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0895475-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-10 | — | — | EP | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | ITGB3 132/4885ITGA2B 106/4885CD274 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.